Paul E Brenchley

List of Publications by Year
in descending order

61	4,186	279487 23	149479 56
papers	citations	h-index	g-index

62	62	62	4538
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	13.9	820
2	Risk HLA-DQA1 and PLA₂R1 Alleles in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 2011, 364, 616-626.	13.9	442
3	Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney International, 2013, 83, 940-948.	2.6	287
4	Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1735-1743.	3.0	270
5	A road map for efficient and reliable human genome epidemiology. Nature Genetics, 2006, 38, 3-5.	9.4	244
6	Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 302-313.	3.0	185
7	Association of the VEGF Gene With Proliferative Diabetic Retinopathy But Not Proteinuria in Diabetes. Diabetes, 2004, 53, 861-864.	0.3	170
8	Membranous nephropathy: integrating basic science into improved clinical management. Kidney International, 2017, 91, 566-574.	2.6	160
9	Global Analysis Reveals the Complexity of the Human Glomerular Extracellular Matrix. Journal of the American Society of Nephrology: JASN, 2014, 25, 939-951.	3.0	158
10	Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1386-1392.	2.2	152
11	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	5.8	120
12	The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenesis and Tissue Repair, 2013, 6, 18.	3.4	110
13	Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2013, 24, 677-683.	3.0	108
14	The Emergence of Networks in Human Genome Epidemiology. Epidemiology, 2007, 18, 1-8.	1.2	102
15	The anti-PLA2R antibody in membranous nephropathy: what we know and what remains aÂdecade after its discovery. Kidney International, 2019, 96, 1292-1302.	2.6	97
16	Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney International, 1992, 41, 933-937.	2.6	72
17	Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies. Nephrology Dialysis Transplantation, 2017, 32, 325-332.	0.4	63
18	Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney International, 1995, 48, 1953-1958.	2.6	51

#	Article	IF	Citations
19	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron, 2015, 130, 159-168.	0.9	49
20	Subcutaneous interstitial pressure and volume characteristics in renal impairment associated with edema. Kidney International, 2013, 84, 980-988.	2.6	46
21	Membranous nephropathy: thinking through the therapeutic options. Nephrology Dialysis Transplantation, 2017, 32, i22-i29.	0.4	35
22	Transforming growth factor Î²-induced peritoneal fibrosis is mouse strain dependent*. Nephrology Dialysis Transplantation, 2013, 28, 2015-2027.	0.4	27
23	Prospective controlled pilot study of arteriovenous fistula placement using the novel Optiflow device. Journal of Vascular Surgery, 2015, 61, 1020-1025.	0.6	27
24	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney International, 2021, 99, 671-685.	2.6	24
25	Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis. Nephrology Dialysis Transplantation, 2012, 27, 2502-2510.	0.4	23
26	Development of Novel Single-Stranded Nucleic Acid Aptamers against the Pro-Angiogenic and Metastatic Enzyme Heparanase (HPSE1). PLoS ONE, 2012, 7, e37938.	1.1	22
27	PLA2R binds to the annexin A2-S100A10 complex in human podocytes. Scientific Reports, 2017, 7, 6876.	1.6	22
28	Genetics of membranous nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 1493-1502.	0.4	22
29	Development and functional capacity of transplanted rat metanephroi. Nephrology Dialysis Transplantation, 2007, 23, 871-879.	0.4	21
30	Initial Observations using a Novel â€œCineâ€•Magnetic Resonance Imaging Technique to Detect Changes in Abdominal Motion Caused by Encapsulating Peritoneal Sclerosis. Peritoneal Dialysis International, 2011, 31, 287-290.	1.1	19
31	Healthcare decision-making in end stage renal disease-patient preferences and clinical correlates. BMC Nephrology, 2015, 16, 189.	0.8	19
32	Frequent elevation of tissue polypeptide antigen in the sera of workers exposed to bladder carcinogens. International Journal of Cancer, 1978, 22, 542-545.	2.3	18
33	Barriers to successful implementation of care in home haemodialysis (BASIC-HHD):1. Study design, methods and rationale. BMC Nephrology, 2013, 14, 197.	0.8	18
34	Detection of antiâ€epithelial cell antibodies in association with pediatric renal transplant failure using a novel microcytotoxicity assay. Tissue Antigens, 1991, 37, 152-155.	1.0	16
35	Reverse iontophoresis of urea in health and chronic kidney disease: a potential diagnostic and monitoring tool?. European Journal of Clinical Investigation, 2012, 42, 840-847.	1.7	15
36	Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model. Nephrology Dialysis Transplantation, 2018, 33, 2145-2155.	0.4	15

#	Article	IF	Citations
37	Immunosuppression Is Essential for Successful Allogeneic Transplantation of the Metanephros. Transplantation, 2009, 88, 151-159.	0.5	14
38	Genetic Polymorphisms and Peritoneal Membrane Function. Peritoneal Dialysis International, 2015, 35, 517-529.	1.1	12
39	Towards radiological diagnosis of abdominal adhesions based on motion signatures derived from sequences of cine-MRI images. Physica Medica, 2014, 30, 437-447.	0.4	11
40	Acute Arteriovenous Access Failure: Long-Term Outcomes of Endovascular Salvage and Assessment of Co-Variates Affecting Patency. Nephron, 2015, 129, 241-246.	0.9	11
41	Time to recovery from haemodialysis : location, intensity and beyond. Nephrology, 2016, 21, 1017-1026.	0.7	11
42	Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in antiâ€PLA₂R positive primary membranous nephropathy. Journal of Clinical Apheresis, 2018, 33, 283-290.	0.7	10
43	Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
44	rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial. BMC Research Notes, 2015, 8, 21.	0.6	8
45	Inhibition of chronic vascular rejection by donor-specific blood transfusion is associated with a reduction in transforming growth factor-??1 expression1. Transplantation, 2002, 73, 1573-1581.	0.5	7
46	A Modified in vivo Flow Variation Technique of Microdialysis for Sampling Uremic Toxins in the Subcutaneous Interstitial Compartment. Blood Purification, 2011, 32, 96-103.	0.9	7
47	Self-Cannulation for Haemodialysis: Patient Attributes, Clinical Correlates and Self-Cannulation Predilection Models. PLoS ONE, 2015, 10, e0125606.	1.1	7
48	The investigative burden of membranous nephropathy in the UK. CKJ: Clinical Kidney Journal, 2020, 13, 27-34.	1.4	6
49	A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis. International Journal of Nephrology, 2015, 2015, 1-12.	0.7	5
50	Some factors affecting the quantitation of rheumatoid factors by enzyme immunoassay. Journal of Immunological Methods, 1983, 65, 343-350.	0.6	4
51	Mechanisms of disease: angiogenesis, vascular endothelial growth factor (VEGF) and psoriasis. Journal of the American Academy of Dermatology, 2004, 50, P146.	0.6	3
52	Identification of a Locus on the X Chromosome Linked to Familial Membranous Nephropathy. Kidney International Reports, 2021, 6, 1669-1676.	0.4	3
53	Peptide <scp>GAM</scp> immunoadsorption in <scp>antiâ€PLA₂R</scp> positive autoimmune membranous nephropathy. The <scp>PRISM</scp> trial. Journal of Clinical Apheresis, 2022, 37, 40-53.	0.7	3
54	Connective-Tissue Glycoconjugates of Bovine Tendon and Skin. Biochemical Society Transactions, 1977, 5, 431-433.	1.6	2

#	Article	IF	Citations
55	FP123RESULTS OF SURVEY ON MANAGEMENT OF MEMBRANOUS NEPHROPATHY IN UNITED KINGDOM *ON BEHALF OF UK MN RADAR STEERING GROUP. Nephrology Dialysis Transplantation, 2015, 30, iii108-iii108.	0.4	2
56	The genetic contribution to recurrent autoimmune nephritis. Transplantation Reviews, 2014, 28, 140-144.	1.2	1
57	Recent Approaches to Understanding Clinical Glomerular Disease. Renal Failure, 1996, 18, 705-709.	0.8	0
58	Measuring the thickness of the peritoneal membrane in mice with optical coherence tomography. Proceedings of SPIE, 2011, , .	0.8	0
59	FP424COMPARISON OF TWO FGF23 ELISA KITS. Nephrology Dialysis Transplantation, 2015, 30, iii211-iii212.	0.4	0
60	FP432TREATMENT WITH ORAL PHOSPHATE BINDERS TO A LOW TARGET PHOSPHATE DECREASES FGF23 LEVELS IN DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii215-iii215.	0.4	0
61	Primary Membranous Nephropathy as a Model of Autoimmune Disease. , 2019, , .		0